Rentosertib Made IPF Patients Look Younger on Six Aging Clocks—But It Has Not Reversed Human Aging

Rentosertib has generated attention because a reanalysis of blood-protein data from its Phase IIa idiopathic pulmonary fibrosis (IPF) trial found a consistent shift toward a younger predicted biological age across six proteomic aging clocks. The key distinction is crucial: these clocks are research biomarkers. The study does not show that rentosertib rejuvenates people, extends lifespan, or reverses aging outside a small group of patients with a serious fibrotic lung disease. 39

The headline result: a younger proteomic-age signal at week 4

The original randomized Phase IIa study enrolled 71 people with IPF. A proteomic substudy analyzed longitudinal serum samples from 42 participants at baseline and after 2, 4, and 12 weeks of treatment, measuring 2,841 proteins and applying six independently developed proteomic aging clocks. All six models pointed toward lower predicted biological age in rentosertib-treated groups relative to placebo. 39

The strongest reported signal appeared at week 4 in the 30-mg twice-daily group. On clocks designed to estimate chronological age, participants were estimated to be about 2.7 to 3.5 years younger than placebo. Company communications have also highlighted an approximate 3–4-year result and a larger effect on an individual clock, but the 2.7–3.5-year range is the more useful central comparison. 39

This is an encouraging example of agreement across multiple independently developed models. But agreement among clocks does not convert a biomarker result into evidence of clinical rejuvenation.

What rentosertib is designed to treat

Rentosertib, also known as INS018_055, is an oral investigational inhibitor of TNIK, a kinase associated with fibrosis-related signaling. Insilico Medicine says AI was used both to identify the TNIK target and to design the drug molecule. 39

Its development program is focused on IPF, a progressive fibrotic lung disease—not on aging in generally healthy adults. In the 12-week Phase IIa study, the 60-mg once-daily group reportedly had a 98.4-mL increase in forced vital capacity (FVC), compared with a 20.3-mL decline in the placebo group. That lung-function result is separate from the later proteomic-age analysis. 39

Why researchers think the age signal may not be only a lung-function effect

A major interpretive question is whether lower predicted biological age merely reflects improvement in IPF disease activity. IPF can substantially alter circulating proteins, so a medicine that reduces inflammation or fibrosis could make a proteomic clock read younger without changing systemic aging itself.

The researchers’ argument for a partially independent effect is that the 30-mg twice-daily arm showed changes in age-associated protein patterns while the placebo group followed a more typical aging-like trajectory. That pattern is hypothesis-generating, but it does not prove that TNIK inhibition directly slows or reverses aging mechanisms. 39

A larger trial designed to connect clock changes with clinical outcomes would be needed to distinguish disease improvement from a genuine geroprotective effect.

Why “age reversal” is too strong a conclusion

Several limitations should temper the headline:

• Small, exploratory subgroup: The aging-clock analysis used samples from 42 people, not all 71 participants in the Phase IIa trial. 39
• Short duration: Measurements extended only to week 12, with the strongest reported effect at week 4. A temporary biomarker shift cannot establish durable slowing of aging. 39
• Disease-specific population: Participants had IPF, which itself changes blood-protein profiles. Results cannot be generalized to healthy people. 39
• No validated anti-aging endpoint: Proteomic clocks may be associated with age-related risk, but they are not validated regulatory surrogate endpoints for demonstrating that a drug reverses human aging. 39
• Unresolved safety and efficacy: The Phase IIa trial was primarily intended to assess safety. Seven participants discontinued because of liver toxicity, including four who were also receiving nintedanib. 39

The accurate conclusion is therefore narrower: rentosertib produced a promising, multi-clock predicted biological-age signal in a small IPF trial. Whether that signal represents reduced disease activity, a broader aging-related effect, or both remains unknown.

What happens next: a 52-week Phase III IPF trial

Rentosertib is not approved. A registered Phase III study, sponsored by Insilico Medicine Hong Kong Limited, is planned as a randomized, double-blind, 52-week trial in IPF, with intended enrollment of 320 patients at 47 centers in China. 1

That study’s central job is to determine whether rentosertib delivers durable pulmonary benefit with an acceptable safety profile. Even a successful Phase III IPF result would not, by itself, establish rentosertib as an anti-aging medicine. To make that case, researchers would need prospective evidence that changes in aging clocks predict meaningful improvements in long-term health outcomes.

For now, rentosertib is best viewed as an AI-developed IPF candidate with an intriguing biomarker result—not a proven age-reversal drug.